About this episode
Cody Shandraw is investing in every vertical of the psychedelic space, with particular regards to the real estate needed for clinical infrastructure as psychedelic medicines start to get rolled out in the near future. We discuss his approach to due diligence, the overall state of the psychedelic medicine landscape, and why you can't truly blind a psychedelic clinical trial.
Hosted on Acast. See acast.com/privacy for more information.
Get every episode summarized
Each time Mycopreneur publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from Mycopreneur
Lee Carroll: Ergothioneine in Support of Psychedelic Therapy
Mycopreneur
Adam Miezio: Psychedelics in the Epstein Files
Mycopreneur
Robert Gallery: Ibogaine For Athletes with Traumatic Brain Injuries
Mycopreneur
Melanie Tremblay: The Hidden Dangers of AI-Generated Mushroom Claims
Mycopreneur